Form D · Biotechnology
ORIGEN THERAPEUTICS INC /CA
Emeryville, CA · CIK 0001051842
Offering snapshot reported Aug 12, 2010 · SEC filing
- Reported sold
- $3.74M Offering amount: $5.42M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 28, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2010 | Initial | $3,743,342 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-146290
Source: Form D, filed Aug 12, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David W. Carter | Director, Executive |
| Timothy Harris | Director |
| Robert Kay | Director |
| Spencer Wang | Director |
| Lynda Wijcik | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5885 Hollis Street Suite 165
Emeryville, CA, 94608
Emeryville, CA, 94608